2001-06-08-世界卫生组织-INN_Proposed_List_85_54页_1mb

Summary of International Nonproprietary Names for Pharmaceutical Substances (INN)

Core Content

The document provides information about International Nonproprietary Names for Pharmaceutical Substances (INN), also known as Denominations communes internationales des Substances pharmaceutiques (DCI) and Denominaciones Comunes Internacionales para las Sustancias Farmacéticas (DCI). These names are used to identify pharmaceutical substances in a standardized way across countries. The names listed are under consideration by the World Health Organization (WHO) as Proposed International Nonproprietary Names (Proposed INN).

The inclusion of a name in the Proposed INN list does not imply any recommendation for medical or pharmaceutical use. It is a provisional designation based on information provided by the manufacturer, and WHO does not endorse or comment on the efficacy of the substance. These names are not included in the Cumulative Lists of INNs and will not be revised.

Main Points

• INN/DCI are standardized names for pharmaceutical substances, used globally to avoid confusion due to proprietary names.
• Proposed INN are under review by WHO and are not yet officially recommended.
• The Cumulative List No. 9, 1996 includes both Proposed and Recommended INN/DCI names.
• Comments or objections to proposed names can be submitted within four months of their publication in WHO Drug Information.
• The Proposed INN are based on information from manufacturers and are intended to provide an indication of the substance's potential use.
• WHO does not validate these statements or comment on the efficacy of the substances.

Key Information

Proposed INN: List 85

• Deadline for comments/objections: 31 January 2002.
• Examples of substances:
  • acidum gadocoleticum / gadocoletic acid / acide gadocoléique / ácido gadocolélico: A diagnostic agent with a complex chemical structure.
  • afeletecanum / afeletecan / afeletécan: An antineoplastic substance with a long chemical name.
  • alfimeprasum / alfimeprase / alfimeprasa: An antithrombotic substance.
  • alicaforsenum / alicaforsen: A diuretic substance with a long chemical name.
  • ambrisentanum / ambrisentan: An antibiotic with a complex structure and molecular formula.
  • darbepoetinum / darbepoetin alfa: An antianaemic substance with a specific molecular formula.
  • enfuvirtidum / enfuvirtide: An antiviral substance with a long chemical name.
  • febuxostatum / febuxostat: An inhibitor of xanthine oxidase and dehydrogenase.
  • gadomelitolum / gadomelitol: A diagnostic agent with a complex structure.
  • gefitinibum / gefitinib: An antineoplastic substance with a specific molecular formula.
  • ingliforibum / ingliforib: An antidiabetic substance with a specific molecular formula.

Additional Notes

• The chemical names and molecular formulas are provided in multiple languages: Latin, English, French, Spanish.
• Some entries include CAS registry numbers, which are unique identifiers for chemical substances.
• Graphic formulas are also mentioned, though they are not fully displayed in the text.
• Glycosylation sites are noted for certain substances, indicating the positions where sugars are attached.

Conclusion

The document serves as a notice of proposed INN/DCI names for pharmaceutical substances, emphasizing that these names are not yet officially recommended and are based on manufacturer-provided information. It highlights the importance of standardized naming in the pharmaceutical industry and outlines the process for submitting feedback to the WHO INN Programme.